share_log

中國生物製藥：自願公告 - 52項研究成果將在2024年ASCO年會公佈

SINO BIOPHARM: VOLUNTARY ANNOUNCEMENT - 52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING

Hong Kong Stock Exchange ·  Apr 29 22:42
Summary by Futu AI
中國生物製藥有限公司宣佈，將於2024年美國臨床腫瘤學會年會公佈52項研究成果，包括1類創新藥「安羅替尼」、「艾貝格司亭α」、「派安普利單抗」等，以及在研創新藥項目「FS222」、「貝莫蘇拜單抗」等。這些研究涵蓋多個瘤種的臨床與基礎研究，其中包括兩項口頭報告，分別是FS222的首次人體試驗和安羅替尼聯合抗PD-L1抗體治療腺泡狀軟組織肉瘤的II期研究。此外，還有多項壁報展示和摘要收錄，展示了公司在腫瘤治療領域的深入研究和創新成果。公司董事會成員包括七位執行董事和五位獨立非執行董事。
中國生物製藥有限公司宣佈，將於2024年美國臨床腫瘤學會年會公佈52項研究成果，包括1類創新藥「安羅替尼」、「艾貝格司亭α」、「派安普利單抗」等，以及在研創新藥項目「FS222」、「貝莫蘇拜單抗」等。這些研究涵蓋多個瘤種的臨床與基礎研究，其中包括兩項口頭報告，分別是FS222的首次人體試驗和安羅替尼聯合抗PD-L1抗體治療腺泡狀軟組織肉瘤的II期研究。此外，還有多項壁報展示和摘要收錄，展示了公司在腫瘤治療領域的深入研究和創新成果。公司董事會成員包括七位執行董事和五位獨立非執行董事。
China Biopharmaceuticals Limited announced that 52 research results will be announced at the 2024 Annual Meeting of the American Society of Clinical Oncology, including Class 1 innovative drugs “Alotini”, “Ebergistin α”, “Piamoplitananti”, etc., as well as innovative drug projects “FS222”, “bemosubicone-resistant, etc.” These studies cover clinical and baseline studies in multiple tumor types, including two oral reports, a first-in-human trial of FS222 and a Phase II study for the treatment of bubonic soft tissue carcinoma with alotinine combined anti-PD-L1 antibodies. In addition, there are several wall paper presentations and abstracts showcasing the company's deep research and innovation in the field of oncology treatment. The Company's Board of Directors consists of seven executive directors and five independent non-executive directors.
China Biopharmaceuticals Limited announced that 52 research results will be announced at the 2024 Annual Meeting of the American Society of Clinical Oncology, including Class 1 innovative drugs “Alotini”, “Ebergistin α”, “Piamoplitananti”, etc., as well as innovative drug projects “FS222”, “bemosubicone-resistant, etc.” These studies cover clinical and baseline studies in multiple tumor types, including two oral reports, a first-in-human trial of FS222 and a Phase II study for the treatment of bubonic soft tissue carcinoma with alotinine combined anti-PD-L1 antibodies. In addition, there are several wall paper presentations and abstracts showcasing the company's deep research and innovation in the field of oncology treatment. The Company's Board of Directors consists of seven executive directors and five independent non-executive directors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.